A European review committee has recommended that British company GW Pharmaceuticals’ Epidyolex (known as Epidiolex in the US) be licensed as a medicine in the European Union. It could become the first official CBD-based medicine available in Europe after the panel recommended the licensing of therapeutic drugs in the union.
Written by CannIntelligence || 31st July 2019 || News analysis | Companies | Health and science | Policy and Politics | Regulation and legislation | Europe